Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Olezarsen Vial vs Autoinjector
NCT05579860Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- May 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olezarsen in familial chylomicronemia syndrome (FCS) and hypertriglyceridemia (2 arms), sponsored by Ionis Pharmaceuticals. Primary endpoints: Area under the plasma concentration-time curve from time 0 to 336 hours and Maximum plasma concentration at Day 91. Started Oct 2022; status: completed.
02
Drugs
olezarsen
03
Conditions
familial chylomicronemia syndrome (FCS)hypertriglyceridemia
Beyond the preview
Go deeper on NCT05579860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579860.